Cellosaurus logo
expasy logo

Cellosaurus Mel-RMu/DR2 (CVCL_T017)

[Text version]
Cell line name Mel-RMu/DR2
Synonyms MelRMu DR2; Mel-RMU-DR2
Accession CVCL_T017
Resource Identification Initiative To cite this cell line use: Mel-RMu/DR2 (RRID:CVCL_T017)
Comments Selected for resistance to: ChEBI; CHEBI_75045; Dabrafenib (Tafinlar; GSK2118436).
Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
Sequence variations
  • Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; HGNC:9612; PTK2B; Simple; p.Arg429Cys (c.1285C>T); dbSNP=rs201274282; Zygosity=Heterozygous (from parent cell line).
Disease Melanoma (NCIt: C3224)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_S994 (Mel-RMu)
Sex of cell Sex unspecified
Age at sampling Age unspecified
Category Cancer cell line
Publications

PubMed=22437314; DOI=10.1038/jid.2012.63
Gowrishankar K., Snoyman S., Pupo G.M., Becker T.M., Kefford R.F., Rizos H.
Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
J. Invest. Dermatol. 132:1850-1859(2012)

Cross-references
Cell line databases/resources cancercelllines; CVCL_T017
Encyclopedic resources Wikidata; Q54905131
Polymorphism and mutation databases Cosmic; 1941943
Entry history
Entry creation03-Feb-2014
Last entry update19-Dec-2024
Version number16